Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys

Annals of Neurology

Volumn 75, Issue 3, 2014, Pages 351-362

  Recasens, Ariadna ^a   Dehay, Benjamin ^b,c   Bové, Jordi ^a   Carballo Carbajal, Iria ^a   Dovero, Sandra ^b,c   Pérez Villalba, Ana ^d   Fernagut, Pierre Olivier ^b,c   Blesa, Javier ^e   Parent, Annabelle ^a   Perier, Celine ^a   Fariñas, Isabel ^d   Obeso, José A ^e   Bezard, Erwan ^b,c   Vila, Miquel ^a,f,g  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^d UNIVERSITY OF VALENCIA   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEINASE K;

ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENDOCYTOSIS; FEMALE; GLOBUS PALLIDUS; HAPLORHINI; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOGOLD LABELING; IMMUNOREACTIVITY; INNERVATION; LEWY BODY; MOLECULAR WEIGHT; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SUPERIOR FRONTAL GYRUS; SYNAPTOSOME; TEMPORAL CORTEX;

ALPHA-SYNUCLEIN; ANIMALS; CORPUS STRIATUM; DOPAMINERGIC NEURONS; FEMALE; HUMANS; LEWY BODIES; MACACA MULATTA; MICE; MICE, KNOCKOUT; MICROINJECTIONS; NERVE DEGENERATION; PARKINSON DISEASE; SUBSTANTIA NIGRA; TISSUE EXTRACTS;

EID: 84897977607     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24066     Document Type: Article

References (41)

1. Goedert M, Spillantini MG, Del Tredici K, et al. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9: 13-24.
2. Spillantini MG, Schmidt ML, Lee VMY, et al. alpha-Synuclein in Lewy bodies. Nature 1997; 388: 839-840.
3. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-164.
4. Spillantini MG, Crowther RA, Jakes R, et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998; 95: 6469-6473.
5. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
6. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-1157.
7. Ulusoy A, Rusconi R, Perez-Revuelta BI, et al. Caudo-rostral Brain Spreading of alpha-Synuclein through Vagal Connections. EMBO Mol Med 2013; 5: 1051-1059.
8. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506.
9. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503.
10. Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949-953.
11. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012; 209: 975-986.
12. Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 2013; 136: 1128-1138.
13. Iwatsubo T, Yamaguchi H, Fujimuro M, et al. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol 1996; 148: 1517-1529.
14. Rousseau E, Dehay B, Ben Haiem L, et al. Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation. Proc Natl Acad Sci U S A 2004; 101: 9648-9653.
15. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25: 239-252.
16. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001; 21: 6853-6861.
17. Dehay B, Bove J, Rodriguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010; 30: 12535-12544.
18. Giasson BI, Jakes R, Goedert M, et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human a-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res 2000; 59: 533.
19. Giasson B, Duda JE, Quinn SM, et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002; 34: 521-533.
20. Waxman EA, Duda JE, Giasson BI,. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol 2008; 116: 37-46.
21. Collantes M, Penuelas I, Alvarez-Erviti L, et al. Use of 11C-(+)-alpha -dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease [in Spanish]. Rev Esp Med Nucl 2008; 27: 103-111.
22. Kramer ML, Schulz-Schaeffer WJ,. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27: 1405-1410.
23. Prusiner SB, McKinley MP, Bowman KA, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 1983; 35: 349-358.
24. Scherzinger E, Lurz R, Turmaine M, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997; 90: 549-558.
25. Kuusisto E, Parkkinen L, Alafuzoff I,. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003; 62: 1241-1253.
26. Cremades N, Cohen SI, Deas E, et al. Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 2012; 149: 1048-1059.
27. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012; 32: 13454-13469.
28. Ueda T, Greengard P, Berzins K, et al. Subcellular distribution in cerebral cortex of two proteins phosphorylated by a cAMP-dependent protein kinase. J Cell Biol 1979; 83: 308-319.
29. Burke RE, O'Malley K,. Axon degeneration in Parkinson's disease. Exp Neurol 2013; 246: 72-83.
30. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013; 136: 2419-2431.
31. Hansen C, Angot E, Bergstrom AL, et al. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-725.
32. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010-13015.
33. Sung JY, Kim J, Paik SR, et al. Induction of neuronal cell death by rab5a-dependent endocytosis of alpha-synuclein. J Biol Chem 2001; 276: 27441-27448.
34. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57-71.
35. Muntane G, Ferrer I, Martinez-Vicente M,. α-Synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 2012; 200: 106-119.
36. Sulzer D, Surmeier DJ,. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord 2013; 28: 715-724.
37. Lundblad M, Decressac M, Mattsson B, et al. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 2012; 109: 3213-3219.
38. Olanow CW, Prusiner SB,. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 2009; 106: 12571-12572.
39. Marques O, Outeiro TF,. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 2012; 3: e350.
40. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20: 419-425.
41. Wang Y, Shi M, Chung KA, et al. Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med 2012; 4: 121ra20.